Invention Grant
US09346816B2 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
有权
6,7,8,9-四氢-5H-1,4,7,10a-四氮杂 - 环庚烯并[f]茚衍生物，含有这些化合物的药物组合物，它们的用途和制备方法
![6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them](/docs/US/2016-05-24/US09346816B2/abs.jpg.600x600.jpg)
- Patent Title: 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
- Patent Title (中): 6,7,8,9-四氢-5H-1,4,7,10a-四氮杂 - 环庚烯并[f]茚衍生物，含有这些化合物的药物组合物，它们的用途和制备方法
-
Application No.: US14072324Application Date: 2013-11-05
-
Publication No.: US09346816B2Publication Date: 2016-05-24
- Inventor: Stephan-Georg Mueller , Christopher John Brown , Alexander Heifetz , Bernd Nosse , Juergen Prestle , Natacha Prevost , Klaus Rudolf , Stefan Scheuerer , Marcus Schindler , Dirk Stenkamp , Leo Thomas , Heather Tye
- Applicant: Stephan-Georg Mueller , Christopher John Brown , Alexander Heifetz , Bernd Nosse , Juergen Prestle , Natacha Prevost , Klaus Rudolf , Stefan Scheuerer , Marcus Schindler , Dirk Stenkamp , Leo Thomas , Heather Tye
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Michael P. Morris; Usha R. Patel
- Priority: EP08170154 20081127
- Main IPC: A61K31/55
- IPC: A61K31/55 ; C07D487/14
![6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them](/abs-image/US/2016/05/24/US09346816B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
Public/Granted literature
Information query
